{"mainPropery":{"diseaseId":1902,"diseaseName":"Tyrosine hydroxylase deficiency","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/1902/tyrosine-hydroxylase-deficiency","synonyms":["Parkinsonism, infantile, autosomal recessive","Dystonia, DOPA responsive, autosomal recessive","DOPA responsive dystonia, autosomal recessive","Segawa syndrome, autosomal recessive","DYT/PARK-TH","Tyrosine hydroxylase-deficient dopa-responsive dystonia","DYT5b","TH-deficient DRD"],"synonyms-with-source":[{"name":"Parkinsonism, infantile, autosomal recessive"},{"name":"Dystonia, DOPA responsive, autosomal recessive"},{"name":"DOPA responsive dystonia, autosomal recessive"},{"name":"Segawa syndrome, autosomal recessive","source":""},{"name":"DYT/PARK-TH","source":"Pubmed"},{"name":"Tyrosine hydroxylase-deficient dopa-responsive dystonia","source":"Orphanet"},{"name":"DYT5b","source":"Orphanet"},{"name":"TH-deficient DRD","source":"GeneReviews"}],"identifiers":[{"identifierType":"OMIM","identifierId":"605407"},{"identifierType":"ORPHANET","identifierId":"101150"},{"identifierType":"UMLS","identifierId":"C1854299"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":142,"resourceName":"Dystonia Medical Research Foundation","abbreviation":"","address1":"1 East Wacker Drive","address2":"Suite 1730","address3":"","address4":"","address5":"","city":"Chicago","state":"IL","zip":"60601-1905","country":"United States","phone":"+1-312-755-0198","tty":"","tollFree":"1-0800-377-3978","fax":"+1-312-803-0138","email":"dystonia@dystonia-foundation.org","url":"https://dystonia-foundation.org/","freeText":""},{"resourceID":272,"resourceName":"Pediatric Neurotransmitter Disease Association","address1":"28 Prescott Place","address2":"","address3":"","address4":"","address5":"","city":"Old Bethpage","state":"NY","zip":"11804","country":"United States","phone":"603-733-8409","tty":"","tollFree":"","fax":"","email":"pnd@pndassociation.org","url":"http://www.pndassoc.org/"}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/605407' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=%28%22Segawa%20syndrome%2C%20autosomal%20recessive%22%5BSupplementary%20Concept%5D%20OR%20%22Segawa%20syndrome%2C%20autosomal%20recessive%22%5BAll%20Fields%5D%20OR%20%22tyrosine%20hydroxylase%20deficiency%22%5BAll%20Fields%5D%29%20AND%20hasabstract%5Btext%5D&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Tyrosine hydroxylase deficiency. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/tyrosine-hydroxylase-deficiency' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Tyrosine hydroxylase deficiency. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C1854299' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1245/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1530,"resourceId":2161,"resourceName":"National Institute of Neurological Disorders and Stroke (NINDS)","descriptionText":"The <a href='http://www.ninds.nih.gov/disorders/dystonias/detail_dystonias.htm' target='_blank'>National Institute of Neurological Disorders and Stroke</a> (NINDS) collects and disseminates research information related to neurological disorders. Click on the link to view information on&nbsp;this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1181084-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=101150' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1437/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1541,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/ClinicalLabs_Search_Simple.php?lng=EN&LnkId=14826&Typ=Pat' target='_blank'>Orphanet</a> lists international laboratories offering diagnostic testing for this condition.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:605407' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":8303,"questionText":"What is tyrosine hydroxylase deficiency?","answerText":"<strong>Tyrosine hydroxylase (TH) deficiency</strong> is a rare inherited condition that affects the <a href=\"http://ghr.nlm.nih.gov/glossary=nervoussystem\" target=\"_blank\">nervous system</a>. There are three different forms of&nbsp;the condition&nbsp;that vary in severity. The mild form is called TH-deficient dopa-responsive <a href=\"http://www.nlm.nih.gov/medlineplus/dystonia.html\" target=\"_blank\">dystonia</a> and typically develops between age twelve months and six years. The two severe forms, which are&nbsp;called infantile parkinsonism&nbsp;and progressive infantile encephalopathy,&nbsp;often begin shortly after&nbsp;birth or during early infancy.&nbsp;Although there is some overlap of features among the three forms, each is associated with unique signs and symptoms. TH deficiency is caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in the <em><a href=\"http://ghr.nlm.nih.gov/gene/TH\" target=\"_blank\">TH</a></em> gene and is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner. Affected people are usually treated with <a href=\"http://www.mayoclinic.org/drugs-supplements/levodopa-oral-route/description/drg-20064498\" target=\"_blank\">levodopa</a> therapy.[8289][8290][8291]","dateModified":"2015-02-16T19:55:00"},"basicQuestions":[{"questionId":8297,"questionText":"What are the signs and symptoms of t<span class=\"title\" itemprop=\"name\">yrosine hydroxylase deficiency?</span>","answerText":"There are three different forms of tyrosine hydroxylase (TH) deficiency that vary in severity. The mild form of the condition is called TH-deficient dopa-responsive <a href=\"http://www.nlm.nih.gov/medlineplus/dystonia.html\" target=\"_blank\">dystonia</a>. Children affected by this form typically develop features of the condition between age twelve months and six years. Symptoms may include an abnormal gait (manner of walking); lack of coordination when walking or running; repetitive, involuntary movements of the arms and/or legs; unusual positioning of limbs; postural <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003192.htm\" target=\"_blank\">tremor</a> (shaking when holding a position); and abnormal, involuntary eye movements. The features of TH-deficient dopa-responsive dystonia tend to get worse over time but are generally responsive to treatment.[8289][8291]<br />\r\n<br />\r\nThe severe form of TH deficiency is called infantile parkinsonism. Children affected by this form generally begin developing features of the condition between age three to twelve months. Signs and symptoms of infantile parkinsonism may include:[8289][8291]\r\n<ul>\r\n    <li>Delayed motor milestones (i.e. sitting up, crawling, walking)</li>\r\n    <li>Intellectual disability</li>\r\n    <li>Speech problems</li>\r\n    <li>Muscle stiffness, especially in the arms and legs</li>\r\n    <li>Unusual positioning of body</li>\r\n    <li><a href=\"http://www.intelihealth.com/print-article/drooping-eyelid-ptosis\" target=\"_blank\">Ptosis</a></li>\r\n    <li>Abnormal, involuntary eye movements</li>\r\n    <li>Constipation</li>\r\n    <li><a href=\"http://www.niddk.nih.gov/health-information/health-topics/digestive-diseases/ger-and-gerd-in-infants/Pages/facts.aspx\" target=\"_blank\">Gastroesophageal reflux</a></li>\r\n    <li>Difficulty regulating body temperature, blood sugar and blood pressure</li>\r\n    <li>Mental health conditions (i.e. depression, anxiety, or obsessive-compulsive behaviors)</li>\r\n</ul>\r\n<br />\r\nThe very severe form of TH deficiency which is&nbsp;called progressive infantile encephalopathy, generally develops before age three to six months. Early symptoms may include fetal distress; feeding difficulties; low muscle tone; and small head circumference, height and/or weight from birth. Babies affected by this form generally have severe physical and intellectual disability due to underlying brain dysfunction and structural abnormalities. Other signs and symptoms include severe delay in motor milestones; rigidity and/or spasticity of arms and legs; ptosis of both eye lids; and episodes of profuse sweating, lethargy, irritability and/or excessive drooling.[8290][8291]","dateModified":"2015-02-16T10:03:00","resourceClassificationName":"Symptoms","references":[{"referenceId":8289,"authors":"","articleTitle":"Tyrosine hydroxylase deficiency","bookWebsiteJournalTitle":"Genetic Home Reference","date":"April 2009","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/tyrosine-hydroxylase-deficiency","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8290,"authors":"","articleTitle":"Tyrosine hydroxylase deficiency","bookWebsiteJournalTitle":"NORD","date":"April 2014","volume":"","pages":"","url":"http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1245/viewAbstract","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8291,"authors":"Yoshiaki Furukawa, MD, PhD and Stephen Kish, PhD","articleTitle":"Tyrosine Hydroxylase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1437/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8298,"questionText":"What causes tyrosine hydroxylase deficiency?","answerText":"Tyrosine hydroxylase (TH) deficiency is caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in the <em><a href=\"http://ghr.nlm.nih.gov/gene/TH\" target=\"_blank\">TH</a></em> gene. This gene encodes an <a href=\"http://www.genome.gov/Glossary/index.cfm?id=58\" target=\"_blank\">enzyme</a> that helps convert certain amino acids (building blocks of protein) to dopamine. Dopamine is a chemical that is important to the function of the nervous system. For example, it helps the brain control movement by acting as a messenger to the other parts of the body. Dopamine can also be made into other chemicals that play an important role in the functioning of the <a href=\"http://www.nlm.nih.gov/medlineplus/autonomicnervoussystemdisorders.html\" target=\"_blank\">autonomic nervous system</a>. Mutations in the <em>TH</em> gene result in reduced levels of dopamine, which&nbsp;leads to&nbsp;the many signs and symptoms associated with TH deficiency.[8289]","dateModified":"2015-02-16T10:40:00","resourceClassificationName":"Cause","references":[{"referenceId":8289,"authors":"","articleTitle":"Tyrosine hydroxylase deficiency","bookWebsiteJournalTitle":"Genetic Home Reference","date":"April 2009","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/tyrosine-hydroxylase-deficiency","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8299,"questionText":"Is tyrosine hydroxylase deficiency inherited?","answerText":"Tyrosine hydroxylase deficiency is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner.[8291] This means that to be affected, a person must have a <a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=\"_blank\">mutation</a> in both copies of the responsible <a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a> in each cell. The parents of an affected person usually each carry one mutated copy of the gene and are referred to as carriers. Carriers typically do not show signs or symptoms of the condition. When two carriers of an autosomal recessive condition have children, each child has a 25% (1 in 4) risk to have the condition, a 50% (1 in 2) risk to be a carrier like each of the parents, and a 25% chance to not have the condition <em>and</em> not be a carrier.","dateModified":"2015-02-16T10:47:00","resourceClassificationName":"Inheritance","references":[{"referenceId":8291,"authors":"Yoshiaki Furukawa, MD, PhD and Stephen Kish, PhD","articleTitle":"Tyrosine Hydroxylase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1437/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8300,"questionText":"How is tyrosine hydroxylase deficiency diagnosed?","answerText":"A diagnosis of tyrosine hydroxylase (TH) deficiency is typically suspected based on the presence of characteristic signs and symptoms. Analysis of a small sample of <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003428.htm\" target=\"_blank\">cerebrospinal fluid</a> may be recommended to support the diagnosis and to rule out other conditions associated with similar features. Identification of a disease-causing change (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutation</a>) in each copy of the <a href=\"http://ghr.nlm.nih.gov/gene/TH\" target=\"_blank\"><em>TH</em></a> gene confirms a diagnosis of TH deficiency.[8290][8291]","dateModified":"2015-02-16T10:56:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":8290,"authors":"","articleTitle":"Tyrosine hydroxylase deficiency","bookWebsiteJournalTitle":"NORD","date":"April 2014","volume":"","pages":"","url":"http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1245/viewAbstract","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8291,"authors":"Yoshiaki Furukawa, MD, PhD and Stephen Kish, PhD","articleTitle":"Tyrosine Hydroxylase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1437/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8301,"questionText":"How might tyrosine hydroxylase deficiency be treated?","answerText":"People affected by tyrosine hydroxylase (TH) deficiency are generally treated with a medication called <a href=\"http://www.mayoclinic.org/drugs-supplements/levodopa-oral-route/description/drg-20064498\" target=\"_blank\">levodopa</a>. The effectiveness of levodopa therapy varies significantly depending on the severity of the condition. People affected by the mild form of TH deficiency (TH-deficient dopa-responsive <a href=\"http://www.nlm.nih.gov/medlineplus/dystonia.html\" target=\"_blank\">dystonia</a>) generally respond well to treatment. In most cases, this medication is able to drastically improve or even completely alleviate associated symptoms.[8290][8291] <br />\r\n<br />\r\nUnfortunately,&nbsp;children with infantile parkinsonism or&nbsp;progressive infantile encephalopathy (the two severe forms of TH deficiency) may have an incomplete response to levodopa, or it may take several months to several years to see an improvement in symptoms. In many cases, affected&nbsp;children are also extremely sensitive to the drug and may experience negative side affects such as difficulties in performing voluntary movements (dyskinesia), vomiting and appetite suppression of appetite.[8290][8291]","dateModified":"2015-02-16T15:19:00","resourceClassificationName":"Treatment","references":[{"referenceId":8290,"authors":"","articleTitle":"Tyrosine hydroxylase deficiency","bookWebsiteJournalTitle":"NORD","date":"April 2014","volume":"","pages":"","url":"http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1245/viewAbstract","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8291,"authors":"Yoshiaki Furukawa, MD, PhD and Stephen Kish, PhD","articleTitle":"Tyrosine Hydroxylase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1437/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8302,"questionText":"What is the long-term outlook for people with tyrosine hydroxylase deficiency?","answerText":"The long-term outlook (prognosis) for people with tyrosine hydroxylase (TH)&nbsp;deficiency varies based on the severity of the condition. The mild form of TH deficiency (TH-deficient dopa-responsive <a href=\"http://www.nlm.nih.gov/medlineplus/dystonia.html\" target=\"_blank\">dystonia</a>) is generally associated with a good prognosis. People affected by this form&nbsp;usually respond quickly and completely to treatment with <a href=\"http://www.mayoclinic.org/drugs-supplements/levodopa-oral-route/description/drg-20064498\" target=\"_blank\">levodopa</a>, often seeing a full reversal of symptoms.[8289][8290][8291] <br />\r\n<br />\r\nUnfortunately, babies affected by infantile parkinsonism&nbsp;or progressive infantile encephalopathy generally experience more severe <a href=\"http://rarediseases.info.nih.gov/gard/1902/tyrosine-hydroxylase-deficiency/resources/9\" target=\"_blank\">signs and symptoms</a> than those affected by TH-deficient dopa-responsive dystonia. These severe forms of TH deficiency are also more difficult to effectively treat and therefore, tend to have a worse prognosis.[8290][8291]","dateModified":"2015-02-16T15:47:00","resourceClassificationName":"Prognosis","references":[{"referenceId":8289,"authors":"","articleTitle":"Tyrosine hydroxylase deficiency","bookWebsiteJournalTitle":"Genetic Home Reference","date":"April 2009","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/tyrosine-hydroxylase-deficiency","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8290,"authors":"","articleTitle":"Tyrosine hydroxylase deficiency","bookWebsiteJournalTitle":"NORD","date":"April 2014","volume":"","pages":"","url":"http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1245/viewAbstract","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8291,"authors":"Yoshiaki Furukawa, MD, PhD and Stephen Kish, PhD","articleTitle":"Tyrosine Hydroxylase Deficiency","bookWebsiteJournalTitle":"GeneReviews","date":"July 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1437/","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":9817,"relatedDiseaseName":"Dopa-responsive dystonia","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":13598,"phenoTypeName":"Babinski sign","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13456,"phenoTypeName":"Bradykinesia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10650,"phenoTypeName":"Brisk reflexes","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":4240,"phenoTypeName":"Central hypotonia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13409,"phenoTypeName":"Constipation","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":7364,"phenoTypeName":"Decreased CSF homovanillic acid","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14142,"phenoTypeName":"Delayed speech and language development","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":7362,"phenoTypeName":"Excessive salivation","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13239,"phenoTypeName":"Feeding difficulties","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10331,"phenoTypeName":"Focal dystonia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13455,"phenoTypeName":"Gait ataxia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11447,"phenoTypeName":"Hypokinesia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10038,"phenoTypeName":"Irritability","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8721,"phenoTypeName":"Lethargy","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5213,"phenoTypeName":"Limb dystonia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5171,"phenoTypeName":"Lower limb hyperreflexia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8729,"phenoTypeName":"Motor delay","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10639,"phenoTypeName":"Myoclonus","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":12206,"phenoTypeName":"Night sweats","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14241,"phenoTypeName":"Oculogyric crisis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9388,"phenoTypeName":"Parkinsonism","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3896,"phenoTypeName":"Pes cavus","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13849,"phenoTypeName":"Postural tremor","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5615,"phenoTypeName":"Ptosis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13451,"phenoTypeName":"Rigidity","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3899,"phenoTypeName":"Talipes equinovarus","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13043,"phenoTypeName":"Fever","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13660,"phenoTypeName":"Generalized dystonia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8722,"phenoTypeName":"Intellectual disability, mild","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9384,"phenoTypeName":"Generalized hypotonia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":5206,"phenoTypeName":"Progressive encephalopathy","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":6245,"phenoTypeName":"Infantile onset","percentRanges":"-"},{"phenoTypeId":9896,"phenoTypeName":"Mask-like facies","percentRanges":"-"},{"phenoTypeId":3421,"phenoTypeName":"Muscular hypotonia of the trunk","percentRanges":"-"},{"phenoTypeId":14325,"phenoTypeName":"Parkinsonism with favorable response to dopaminergic medication","percentRanges":"-"},{"phenoTypeId":9423,"phenoTypeName":"Tremor","percentRanges":"-"},{"phenoTypeId":7381,"phenoTypeName":"Variable expressivity","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Tyrosine_hydroxylase_deficiency"}